Adoptive cell therapy (ACT) is a treatment that uses a cancer patient's own T lymphocytes with anti-tumour activity, expanded in vitro and reinfused into the patient with cancer.
ACT using autologous tumour-infiltrating lymphocytes is currently the most effective treatment for patients with metastatic melanoma and can mediate objective tumour regressions in 50% of patients.
Lymphodepletion before ACT is an important component of the treatment because it eliminates T regulatory cells and eliminates lymphocytes, which compete with the transferred cells for homeostatic cytokines such as interleukin 7 (IL7) and IL15.
ACT can be effective in treating selected patients with post-transplant lymphoproliferative diseases (PTLD) resulting from Epstein–Barr virus, which can cause PTLD during the immunosuppressed state.
Recent studies have shown that genetic modification of lymphocytes using retroviruses that encode T-cell receptors can convert normal lymphocytes into lymphocytes with anti-cancer activity. The adoptive transfer of these lymphocytes into patients with metastatic melanoma can mediate tumour regression.
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rosenberg, S. A. et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988). The first paper to demonstrate the regression of cancer using TIL for the immunotherapy of patients with metastatic melanoma.
Dudley, M. E. et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science 298, 850–854 (2002).
Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005). References 2 and 3 demonstrate that lymphodepletion prior to ACT can lead to increased cancer regression as well as clonal repopulation of patients with anti-tumour lymphocytes.
Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006). The first paper demonstrating the adoptive cell transfer of lymphocytes transduced with a retrovirus encoding TCRs that recognize a cancer antigen can mediate anti-tumour responses in patients with metastatic melanoma.
Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485–1492 (1985).
Rosenberg, S. A., Yang, J. C., White, D. E. & Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann. Surg. 228, 307–319 (1998).
Lotze, M. T. et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings. J. Am. Med. Assoc. 256, 3117–3124 (1986).
Kammula, U. S., White, D. E. & Rosenberg, S. A. Trends in the safety high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83, 797–805 (1998).
Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).
Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053 (2005).
Van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991).
Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281–287 (1999).
Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909–915 (2004).
Rosenberg, S. A. et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169–6176 (2005). The demonstration that peptide vaccines are capable of generating large numbers of anti-tumour lymphocytes in vivo , but these lymphocytes do not appear to have any in vivo ability to prevent recurrence.
Mitchison, N. A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102, 157–177 (1955). A seminal paper demonstrating the role of the cellular immune response in the rejection of tumour transplants.
Delorme, E. J. & Alexander, P. Treatment of primary fibrosarcoma in the rat with immune lymphocytes. Lancet 2, 117–120 (1964).
Fefer, A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 29, 2177–2183 (1969).
Cheever, M. A., Kempf, R. A. & Fefer, A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J. Immunol. 119, 714–718 (1977).
Eberlein, T. J., Rosenstein, M. & Rosenberg, S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J. Exp. Med. 156, 385–397 (1982). Demonstration that the intravenous administration of anti-tumour lymphocytes expanded in IL2 could mediate the regression of established disseminated syngeneic tumours in mice.
Donohue, J. H. et al. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocyte to cure a disseminated syngeneic lymphoma. J. Immunol. 132, 2123–2128 (1984).
Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986). The first demonstration in murine models that the adoptive transfer of TIL could mediate the regression of established murine tumours.
Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569–580 (2003). This paper demonstrated that adoptive cell transfer, vaccine and IL2 administration could mediate the rejection of large established transgenic B16 melanomas in mice.
Antony, P. A. et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591–2601 (2005).
Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907–912 (2005).
Wrzesiniski, C. et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117, 492–501 (2007).
Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616–1626 (2005).
Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197–2204 (2007).
Abad, J. D. et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31, 1–6 (2008).
Muul, L. M., Spiess, P. J., Director, E. P. & Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989–995 (1987). The first description of the ability of TIL in the human to recognize human tumour antigens presented on cancer cells.
Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332–342 (2003).
Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl Cancer Inst. 86, 1159–1166 (1994).
Aebersold, P. et al. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J. Natl Cancer Inst. 13, 932–937 (1991).
Schwartzentruber, D. J. et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12, 1475–1483 (1994).
Rosenberg, S. A. et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578 (1990).
Dummer, W. et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185–192 (2002).
Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168–16173 (2002).
Robbins, P. F. et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125–7130 (2004). This paper demonstrated that persistence of adoptively transferred cells correlated directly with the likelihood of cancer regression.
Zhou, J., Shen, X., Hodes, R. J., Rosenberg, S. A. & Robbins, P. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046–7052 (2005). The paper shows that the telomere length of the transferred lymphocytes correlated both with in vivo persistence of the transferred cells as well as with tumour regression.
Powell, D. J., Dudley, M. E., Robbins, P. F. & Rosenberg, S. A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 101, 241–250 (2004).
Ochsenbein, A. F. et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200, 1407–1417 (2004).
Marijt, W. A. E. et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA 100, 2742–2747 (2003).
Kolb, H. J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462–2465 (1990). This paper was the first to show that treatment with donor lymphocytes could mediate cytogenetic remissions in patients with chronic myeloid leukaemia.
Mackinnon, S. et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86, 1261–1268 (1995).
Riddell, S. R., Bleakley, M., Nishida, T., Berger, C. & Warren, E. H. Adoptive transfer of allogeneic antigen-specific T cells. Biol. Blood Marrow Transplant. 12, 9–12 (2006).
Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994). This paper showed that the infusion of normal donor lymphocytes could achieve complete responses in patients with lymphomas that occurred following the treatment of leukaemia with chemotherapy and T-cell-depleted allogeneic stem cell grafts.
Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 345, 9–13 (1995).
Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998). References 46 and 47 showed that tumour regression could be obtained by the infusion of long-term cultured EBV-specific T-cell lines.
Khanna, R. et al. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10391–10396 (1999).
Haque, T. et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein–Barr virus-specific cytotoxic T cells. Transplantation 72, 1399–1402 (2001).
Haque, T. et al. Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lymphoproliferative disease: results of a phase 2 multicentre clinical trial. Blood 110, 1123–1131 (2007).
Straathof, K. et al. Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes. Blood 105, 1898–1904 (2005).
Comoli, P. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23, 8942–8949 (2005).
Bollard, C. et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus Hodgkin's disease. J. Exp. Med. 200, 1623–1633 (2004).
Riddell, S. R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238–241 (1992).
Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nature Rev. Cancer 3, 35–45 (2003).
Murphy, A. et al. Gene modification strategies to induce tumor immunity. Immunity 22, 403–414 (2005).
Cole, D. J. et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55, 748–752 (1995).
Hughes, M. S. et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene. Ther. 16, 457–472 (2005).
Morgan, R. A. et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171, 3287–3295 (2003).
Zhao, Y. et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415–4423 (2005).
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878–8886 (2006).
Cohen, C. J. et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898–3903 (2007).
Theobald, M. B. J., Dittmer, D., Levine, A. J. & Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA 92, 11993–11997 (1995).
Kuball, J., Schmitz, F. W. & Voss, R. H. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22, 117–129 (2005).
Cohen, C. J. et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175, 5799–5808 (2005). References 58–65 demonstrate that TCRs can be identified that recognize cancer antigens and that transduction of these TCRs into normal human cells can transfer this antigen recognition.
Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nature Biotech. 23, 349–354 (2005).
Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024–10028 (1989).
Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).
Park, J. R. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825–833 (2007).
Brentjens R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med. 9, 279–286 (2003).
Johnson, L. A. et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating. J. Immunol. 177, 6548–6559 (2006).
Fernandez-Cruz, E., Woda, B. A. & Feldman, J. D. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J. Exp. Med. 152, 823–841 (1980).
Berendt, M. J. & North, R. J. T-cell-mediated suppression of anti-tumor immunity: an explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151, 69–80 (1980).
Mule, J. J., Shu, S., Schwarz, S. L. & Rosenberg, S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225, 1487–1489 (1984).
Liu, K. & Rosenberg, S. A. Transduction of an interleukin-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356–6365 (2001).
Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Rev. Immunol. 6, 595–601 (2007).
Ruggeri, L., Mancusi, A., Capanni, M., Martelli, M. F. & Velardi, A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol. 17, 211–217 (2005).
Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. (in the press).
- Adoptive cell therapy
(ACT). The administration of a patient's own (autologous) or donor (allogeneic) anti-tumour lymphocytes following a lymphodepleting preparative regimen.
- Capillary leak syndrome
The loss of intravascular fluid into soft tissues and lung.
- Objective clinical response
The Response Evaluation Criteria in Solid Tumours (RECIST) defines an objective response as a 30% reduction in the sum of the longest diameters of measurable lesions comparing post-treatment with pretreatment values. The World Health Organization criterion defines an objective response to be a 50% reduction in the sum of the products of perpendicular diameters of measurable lesions. In both criteria no new lesions can appear.
The relative intensity of reactivity of lymphocytes when interacting with antigen.
Inter-individual genetic variation at the MHC locus. In a partially matched transplant, for example, some MHC antigens are shared by donor and recipient, but in addition the donor has some MHC antigens that the recipient does not.
Lymphodepletion before ACT uses total body irradiation or cytotoxic drugs to deplete the lymphoid compartment of patients.
- Central memory cells
A subset of antigen-reactive lymphocytes with markers such as CD62L and CCR7 that indicate a less differentiated phenotype.
- Antigen-presenting cells
(APC). A subset of cells that have characteristics enabling them to efficiently present antigenic epitopes to lymphocytes (for example, dendritic cells).
Relatively modest to moderate doses of chemotherapy are given, not to attack the cancer, but just to suppress the immune system for a brief period of a week or so.
- Effector phenotype
A constellation of cell surface markers that indicate that lymphocytes have differentiated into a mature effector cell capable of recognizing antigen and lysing target cells or secreting cytokines when encountering antigen.
An antigen that exists in alternative (allelic) forms in a species, thus inducing an immune response when one form is transferred to members of the species who lack it.
- Buffy coat cells
The plasma layer containing enriched white blood cells that results when whole blood is centrifuged.
- Chronic phase
Indolent phase of the disease in patients with chronic myeloid leukaemia.
- Blast crisis
Aggressive acute phase of the disease in patients with chronic myeloid leukaemia.
- Graft-versus-host disease
Inflammatory and tissue-destructive immune reactions that result from the attack on host tissues by infused allogeneic lymphocytes.
- Post-transplant lymphoproliferative disease
(PTLD). Neoplastic proliferation of lymphocytes that occurs in patients undergoing immunosuppresion, often in preparation for bone marrow or organ transplantation; can occur in host or recipient cells.
- Reed–Sternberg cells
Cells with a characteristic morphology that are thought to be the malignant cells in patients with Hodgkin lymphoma.
The process that ensures that B- and T-cell repertoires are biased against self-reactivity, reducing the likelihood of autoimmunity.
- Carcinoembryonic antigen
A protein found in fetal gastrointestinal tissue that can be upregulated in some gastrointestinal cancers and can serve as a marker of tumour burden.
- Cancer–testis antigen
A class of antigenic proteins present on some human cancers but not on adult normal tissues except for testes.
About this article
Cite this article
Rosenberg, S., Restifo, N., Yang, J. et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8, 299–308 (2008). https://doi.org/10.1038/nrc2355
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
International Journal of Molecular Sciences (2021)
Biologia Futura (2021)
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling
Molecular Medicine (2021)
Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells
Scientific Reports (2021)